CytoAgents Inc. (the Company), a clinical-stage biotechnology company, dedicated to developing a safe and effective treatment for Cytokine Release Syndrome (CRS), announced today that it has been awarded a $2 million National Institutes of Health…
Ernst & Young LLP (EY US) today announced that Teresa Whalen, RPh, CEO of CytoAgents, was named an Entrepreneur Of The Year® 2023 East Central Award finalist.
Addition of Arthur P. Bertolino Brings World Class Capabilities to Leadership Team, Positions CytoAgents for Phase 1b/2a Clinical Trials and Strategic Pharma Partnerships to Treat Cytokine Release Syndrome
EY announced today that Teresa Whalen, CEO of CytoAgents, a biotech company developing a therapeutic treatment for Cytokine Release Syndrome, is one of the women founders selected for the EY Entrepreneurial Winning Women™ North America Class of 2021. The…
PITTSBURGH–(BUSINESS WIRE)–CytoAgents, a clinical stage biotechnology company focused on the development of innovative pharmaceutical products for the treatment of life-threatening symptoms associated with Cytokine Release Syndrome (CRS), announced today that it has been awarded a $2…
Harrisburg, PA – Today, Department of Community and Economic Development (DCED) Deputy Secretary Steve D’Ettorre and Ben Franklin Technology Partners Innovation Works CEO Richard Lunak joined Teresa Whalen, CEO of Pittsburgh-based CytoAgents, to highlight the development of…
PITTSBURGH–(BUSINESS WIRE)–CytoAgents, a clinical-stage biotechnology company, announced today that enrollment has started for its Phase 1 clinical trial with lead drug candidate, GP1681, for treatment of COVID-19 “cytokine storm,” clinically known as hypercytokinemia. A randomized, double-blind,…
PITTSBURGH–(BUSINESS WIRE)–CytoAgents a clinical-stage biotechnology company focused on development of pharmaceutical products for the treatment of viral infectious diseases, including COVID-19 and the resulting cytokine storm, announced today that it has received an investment to accelerate…
PITTSBURGH–(BUSINESS WIRE)–CytoAgents, a privately held biotechnology company focused on the development of pharmaceutical products for the treatment of viral infectious diseases, announced today that it has been awarded a National Institutes of Health (NIH) grant to…
Nottingham, U.K., and Pittsburgh–(BUSINESS WIRE)–A collaboration to accelerate the development of a lead COVID-19 drug candidate into human clinical trials was announced today by Quotient Sciences, a leading provider of innovative drug development and manufacturing solutions,…